Psychedelic Clinical Trials: How to Volunteer

Psychedelic research is experiencing a historic comeback. After decades of prohibition that shut down virtually all scientific investigation, substances like psilocybin, MDMA, ketamine, LSD, and DMT are being studied again at some of the most prestigious research institutions in the world. The results so far have been striking enough to attract billions of dollars in funding, FDA Breakthrough Therapy designations, and mainstream media coverage that would have been unthinkable ten years ago.

For people interested in volunteering for clinical trials, this wave of research represents a unique opportunity. Psychedelic studies are actively recruiting participants across the United States and internationally, and they offer a trial experience unlike anything else in clinical research. But the landscape can be confusing — which studies accept healthy volunteers versus patients? How do you find legitimate trials? What is the experience actually like?

This guide answers all of those questions based on current research protocols, published trial data, and the practical realities of participating in psychedelic clinical research in 2026.

“

Psychedelic clinical trials offer a research experience unlike anything else — but most therapeutic studies recruit patients with specific conditions, not healthy volunteers.

The Psychedelic Research Renaissance

The modern era of psychedelic research traces back to the late 1990s and early 2000s, when a handful of researchers began obtaining regulatory approval to study these substances again after a gap of nearly thirty years. Today, the field has exploded. Here are the institutions and organizations leading the charge:

MAPS (Multidisciplinary Association for Psychedelic Studies) has been the most visible advocate for psychedelic research since 1986. Their MDMA-assisted therapy program for PTSD completed Phase 3 trials, and while the FDA declined to approve the initial application from Lykos Therapeutics (the MAPS-founded company) in 2024, requesting additional data, the program continues with supplementary studies. MAPS remains central to the effort to make MDMA-assisted therapy a legal treatment option.

Johns Hopkins Center for Psychedelic and Consciousness Research opened in 2019 with $17 million in funding and has become a global hub for psilocybin research. Their work on psilocybin for treatment-resistant depression and smoking cessation has produced some of the most cited results in the field. The center conducts both patient trials and healthy volunteer studies exploring the neuroscience of psychedelic experiences.

NYU Langone Health has run psilocybin trials since 2006, with landmark studies on end-of-life anxiety in cancer patients. Their research demonstrated that a single psilocybin session could produce rapid and sustained reductions in anxiety and depression in patients with life-threatening diagnoses — results that helped catalyze the broader renaissance.

Imperial College London's Centre for Psychedelic Research was the first dedicated psychedelic research center in the world. Their neuroimaging work has been instrumental in understanding how psychedelics affect brain connectivity, and they have conducted influential trials on psilocybin for depression.

Other major players include the University of California system (UCSF, UCLA, UC Berkeley), Massachusetts General Hospital, Yale, Mount Sinai, the University of Wisconsin-Madison, and a growing number of private companies including Compass Pathways, Usona Institute, Atai Life Sciences, and Cybin. The field has matured from a handful of pioneering labs into a multi-billion-dollar research enterprise.

Types of Psychedelic Trials Currently Recruiting

Psychedelic research is not one monolithic category. Different substances are being studied for different conditions, at different phases, and with very different protocols. Here is what the landscape looks like right now.

Psilocybin (Magic Mushrooms)

Psilocybin is the most actively studied psychedelic compound today. It is the active ingredient in "magic mushrooms" and produces a 4-to-6-hour experience characterized by altered perception, emotional intensity, and often profound changes in perspective. In clinical settings, it is administered as a synthetic capsule — not as raw mushrooms.

Current indications being studied:

• Treatment-resistant depression (TRD) — The most advanced area of psilocybin research. Compass Pathways completed Phase 2b and is running Phase 3 trials. Usona Institute is also in late-stage trials. The FDA granted Breakthrough Therapy designation for psilocybin for TRD.
• Major depressive disorder (MDD) — Several groups are studying psilocybin for depression that has not responded to conventional antidepressants, as well as broader depression populations.
• End-of-life anxiety — Continuing the landmark NYU and Johns Hopkins work on existential distress in patients with terminal illness diagnoses.
• Addiction — Studies on smoking cessation (Johns Hopkins), alcohol use disorder (NYU, University of Wisconsin), and opioid use disorder are ongoing or recently completed.
• PTSD — Emerging trials exploring psilocybin as an alternative or complement to MDMA-assisted therapy for trauma.
• Healthy volunteer studies — Neuroimaging studies, dose-finding studies, and mechanism-of-action research that recruit people without psychiatric conditions.

MDMA (Ecstasy/Molly)

MDMA-assisted therapy for PTSD has been one of the highest-profile psychedelic research programs. MDMA produces a 4-to-6-hour state characterized by emotional openness, reduced fear response, and enhanced empathy — qualities that researchers believe make it uniquely suited for trauma processing within a therapeutic context.

Lykos Therapeutics (formerly the MAPS Public Benefit Corporation) completed two Phase 3 trials that showed MDMA-assisted therapy produced significantly greater PTSD symptom reduction than therapy with a placebo. In August 2024, the FDA declined to approve the initial New Drug Application, citing concerns about functional unblinding and the need for additional safety data. Lykos is conducting supplementary studies to address these concerns, and other organizations are also running MDMA trials.

Ketamine and Esketamine

Ketamine occupies a unique position in the psychedelic landscape because it is already FDA-approved. Esketamine (Spravato), a nasal spray form manufactured by Janssen/Johnson & Johnson, received FDA approval in 2019 for treatment-resistant depression and was later approved for major depressive disorder with suicidal ideation.

Because ketamine is already an approved medication, the clinical trial landscape differs from other psychedelics. Current studies include:

• Trials comparing ketamine to esketamine, or testing different formulations and dosing schedules
• Studies on ketamine for new indications including PTSD, obsessive-compulsive disorder, substance use disorders, and chronic pain
• Research into longer-term outcomes and optimal maintenance protocols
• Combination studies pairing ketamine with psychotherapy modalities

Ketamine trials tend to be more accessible to participants because the drug has a well-established safety profile, and many academic medical centers have active ketamine research programs.

Cannabis and THC

Cannabis research has expanded significantly with the easing of federal restrictions on research-grade cannabis. Studies are investigating THC, CBD, and various cannabinoid combinations for chronic pain, anxiety, PTSD, epilepsy, nausea associated with chemotherapy, and neurological conditions.

Cannabis trials are among the most accessible for volunteers because many study outpatient protocols with relatively low monitoring requirements. Some studies specifically recruit experienced cannabis users, while others seek cannabis-naive participants. Compensation tends to be moderate compared to inpatient psychedelic studies, but the time commitment is often lower.

LSD Microdosing Studies

LSD microdosing — taking sub-perceptual doses (typically 10 to 20 micrograms, compared to a full dose of 100 to 200 micrograms) — has become a major area of interest. Claims about cognitive enhancement, creativity, and mood improvement from microdosing have circulated widely in popular culture, and researchers are now rigorously testing these claims.

Several controlled trials at institutions including the University of Chicago, Imperial College London, and Maastricht University have examined the effects of LSD microdoses on cognition, mood, and creativity. Results so far have been mixed — some studies show subtle cognitive and mood effects while others find little difference from placebo. This is an active area of research that frequently recruits healthy volunteers.

DMT and Ayahuasca

DMT (dimethyltryptamine) is an emerging area of psychedelic research. It produces an intense but short experience when administered intravenously (15 to 30 minutes), making it potentially practical for clinical settings where a full-day psilocybin or MDMA session is not feasible. Small Pharma (now part of Cybin) and other companies are studying intravenous DMT for depression.

Ayahuasca, a traditional Amazonian brew containing DMT along with MAO inhibitors that allow oral absorption, is the subject of observational studies and a small number of clinical trials for depression and addiction. Ayahuasca studies are less common in the U.S. but are conducted at institutions in Brazil, Spain, and other countries.

What the Experience Is Like as a Volunteer

Volunteering for a psychedelic clinical trial is not like showing up for a typical drug study. The protocols are intensive, the experience is deeply personal, and the structure surrounding it is deliberately therapeutic. Here is what a typical psilocybin or MDMA trial looks like from the participant's perspective.

Screening and enrollment. After expressing interest, you will go through an extensive screening process that typically includes a psychiatric evaluation, medical history review, physical exam, blood work, ECG, and sometimes an MRI. For therapeutic trials, researchers need to confirm your diagnosis and ensure you meet all inclusion criteria. This process can take several weeks.

Preparation sessions. Before any dosing, you will meet with the therapists who will be present during your session — usually two trained professionals. Over 2 to 3 preparation sessions (each lasting 60 to 90 minutes), you will build rapport, discuss your intentions, learn what to expect, and develop strategies for navigating the experience. This is a critical part of the protocol and distinguishes psychedelic trials from standard pharmaceutical studies.

“

The preparation, the session, and the integration afterwards are all considered part of the treatment — the drug is just one component of a broader therapeutic framework.

Dosing day. On the day of the session, you will arrive at the research site in the morning. The room is typically set up to be comfortable and non-clinical — a couch or bed with pillows and blankets, dim lighting, and curated music played through headphones. You will receive the study dose (or placebo, if it is a randomized trial) and lie down. Two therapists remain in the room with you for the entire session. They are there to provide support if you need it, but the approach is generally non-directive — they encourage you to turn inward and let the experience unfold.

Vital signs are monitored periodically. For psilocybin, the peak experience typically occurs 2 to 3 hours after dosing and the full session lasts 6 to 8 hours. For MDMA, the active phase lasts 4 to 6 hours. You will remain at the research site until the effects have sufficiently subsided, and someone will need to drive you home.

Integration sessions. In the days and weeks following each dosing session, you will meet with the therapists again for integration — sessions where you process and make sense of the experience. These sessions are considered essential to the therapeutic model. Most protocols include 2 to 3 integration sessions per dosing, and some studies include additional group integration with other participants.

Follow-up assessments. You will complete questionnaires and assessments at regular intervals (often at 1 week, 1 month, 3 months, 6 months, and sometimes 12 months post-dosing) to track the durability of any changes.

Eligibility Requirements

Eligibility for psychedelic trials varies significantly depending on whether the study is recruiting patients or healthy volunteers, and which substance is being studied.

Therapeutic trials (most common): The majority of psychedelic clinical trials recruit participants who have a specific diagnosed condition. For example:

• Psilocybin depression trials typically require a diagnosis of major depressive disorder or treatment-resistant depression, often with documented failure of at least two antidepressant medications
• MDMA PTSD trials require a confirmed PTSD diagnosis, usually assessed using the Clinician-Administered PTSD Scale (CAPS-5)
• Addiction studies require a diagnosis of the specific substance use disorder being targeted (alcohol, tobacco, opioids)

Common exclusion criteria across most psychedelic trials:

• Personal or family history of psychotic disorders (schizophrenia, bipolar I with psychotic features)
• Current use of certain medications, especially SSRIs, SNRIs, MAOIs, and lithium (these can interact with psychedelics or dampen their effects)
• Significant cardiovascular conditions (psychedelics can temporarily raise blood pressure and heart rate)
• Pregnancy or nursing
• Active suicidal ideation with intent
• Current substance use disorder (except in addiction-focused trials)

A note on medication washout: If you are currently taking an antidepressant or other psychiatric medication, many psychedelic trials will require you to taper off under medical supervision before you can participate. This washout period is necessary both for your safety and for the scientific validity of the study, but it can be a significant barrier and should only be done with your prescribing physician's guidance.

Compensation for Psychedelic Studies

Compensation for psychedelic clinical trials varies widely based on the type of study, the number of sessions, the total time commitment, and whether the study is run by a pharmaceutical company or an academic institution.

Typical compensation ranges:

• Phase 1 healthy volunteer studies — $2,000 to $6,000. These studies involve the most monitoring and often require overnight stays or full-day sessions with intensive vital sign and blood sampling.
• Therapeutic trials (psilocybin, MDMA) — $500 to $2,500 total. Many therapeutic studies offer modest per-visit payments ($50 to $150) across preparation, dosing, integration, and follow-up visits. The total adds up over the duration of the study.
• Neuroimaging/fMRI studies — $300 to $1,500. These typically involve 1 to 3 scanning sessions with a psychedelic dose or microdose, plus screening and follow-up.
• Ketamine studies — $500 to $3,000 depending on the number of infusion sessions and follow-up requirements.
• Cannabis studies — $200 to $2,000 depending on duration and whether the study is inpatient or outpatient.
• Microdosing studies — $300 to $1,000. These typically involve taking small doses over several weeks and completing cognitive assessments and questionnaires.

Safety and Supervision

Psychedelic clinical trials have an extensive safety framework that distinguishes them from recreational use. Understanding this framework can help you make an informed decision about participation.

Trained therapists present at all times. During every dosing session, two trained therapists (or a therapist and a physician) remain in the room with you for the entire duration. These are not just monitors — they are specifically trained in psychedelic-assisted therapy, which includes techniques for supporting people through challenging psychological material, grounding exercises, and crisis intervention.

Medical monitoring. Vital signs (blood pressure, heart rate, temperature) are checked regularly throughout the session. A physician is either present or on-call at the research site. Emergency medical equipment and medications are available. Research facilities are typically located within or near a hospital.

Set and setting. Psychedelic researchers take the concept of "set and setting" seriously. "Set" refers to your mindset going into the experience, which is cultivated during preparation sessions. "Setting" refers to the physical and interpersonal environment. Clinical trial dosing rooms are designed to feel comfortable and safe — not like a sterile hospital room. Music selection, lighting, and the therapeutic relationship are all considered part of the treatment.

Dose control and purity. Unlike recreational contexts, clinical trials use pharmaceutical-grade substances at precisely measured doses. You know exactly what you are taking and how much. There is no risk of adulterated substances or unpredictable potency.

How to Find Psychedelic Clinical Trials

Finding legitimate psychedelic trials requires some effort, but there are several reliable channels:

GuineaPig's psychedelic trials category — We aggregate psychedelic studies from ClinicalTrials.gov and present them with estimated compensation, eligibility summaries, and location information. This is the fastest way to see what is currently recruiting near you.

ClinicalTrials.gov — The official U.S. government database of clinical studies. Search for "psilocybin," "MDMA," "ketamine," or "psychedelic" and filter by "Recruiting" status and your location. The interface is not user-friendly, but it is comprehensive.

Research institution websites — Major psychedelic research centers maintain their own recruitment pages. Check Johns Hopkins Center for Psychedelic Research, NYU Langone, UCSF, UCLA, Mount Sinai, and Massachusetts General Hospital. University clinical trial registries are another good source.

MAPS — The Multidisciplinary Association for Psychedelic Studies maintains a list of their active and upcoming trials at maps.org.

Common Concerns Addressed

Legal status. Psilocybin, MDMA, LSD, and DMT remain Schedule I controlled substances under federal law. However, participation in an FDA-authorized clinical trial is completely legal. The research site holds the necessary DEA and FDA authorizations. You never possess or transport the substance — it is administered to you in a clinical setting under supervision.

Drug testing at work. Standard workplace drug panels do not test for psilocybin, LSD, or DMT. MDMA can trigger amphetamine panels for a few days after a dose. THC will show up on standard tests. If your employment involves drug testing, discuss this concern with the research team before enrolling. Some participants request documentation of their trial participation, but whether an employer will accept this is not guaranteed.

Long-term effects. The long-term safety data on psychedelics administered in clinical settings is still limited, but decades of observational research and the recent clinical trials suggest that psychedelics, when administered in controlled settings with proper screening, have a favorable safety profile. The most commonly reported long-term effects are positive — sustained improvements in mood, openness, and life satisfaction. However, negative outcomes including prolonged anxiety, depersonalization, or HPPD (Hallucinogen Persisting Perception Disorder) have been reported in rare cases, primarily in recreational contexts.

Impact on mental health treatment. If you are currently in therapy or taking psychiatric medications, participating in a psychedelic trial could require changes to your treatment plan. Many trials require tapering off antidepressants, which carries its own risks. Always coordinate with your existing mental health providers before making any changes to your treatment.

Placebo possibility. Many psychedelic trials are randomized and placebo-controlled, which means you may receive an inactive placebo instead of the psychedelic substance. Some studies use "active placebos" (like niacin or very low doses) that produce some physical sensations without the full psychedelic effect. If receiving the actual treatment is important to you, ask about the randomization ratio — some studies offer open-label extension phases where all participants eventually receive the active substance.

Frequently Asked Questions